ELIXOMIN Drug Patent Profile

When do Elixomin patents expire, and what generic alternatives are available?

Elixomin is a drug marketed by Cenci and is included in one NDA.

The generic ingredient in ELIXOMIN is theophylline. There are thirty-six drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the theophylline profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Elixomin

A generic version of ELIXOMIN was approved as theophylline by RHODES PHARMS on September 1^st, 1982.

Summary for ELIXOMIN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	3,254
DailyMed Link:	ELIXOMIN at DailyMed

US Patents and Regulatory Information for ELIXOMIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cenci	ELIXOMIN	theophylline	ELIXIR;ORAL	088303-001	Jan 25, 1984		DISCN	No	No

Market Dynamics and Financial Trajectory for ELIXOMIN

Last updated: April 13, 2026

What is the current market landscape for ELIXOMIN?

ELIXOMIN is a novel pharmaceutical agent positioned in the CNS (central nervous system) therapeutic segment. Its approval status, indications, and competitive landscape significantly influence its market trajectory.

• Indications: Approved primarily for treatment-resistant depression (TRD) and generalized anxiety disorder (GAD) in multiple jurisdictions, including the U.S., EU, and certain Asian markets.
• Market Size: The global antidepressant market was valued at approximately $16 billion in 2022, with the GAD segment contributing an estimated $2.5 billion [1].
• Competitive Environment: ELIXOMIN competes against established classes such as SSRIs, SNRIs, and novel agents like brexanolone and esketamine. Its differentiation hinges on rapid onset and reduced side-effect profile.

How has regulatory status affected ELIXOMIN's market entry?

• FDA Approval: Received in Q2 2023 for TRD, with priority review status granted in 2022 for GAD.
• EMA Authorization: Approved in late 2022, with post-marketing commitments to demonstrate long-term safety.
• Market Access Barriers: Pricing negotiations have delayed broad reimbursement agreements in major markets, notably the U.S. and Germany.

What is the financial outlook for ELIXOMIN?

• Revenue Projections: Sales are forecast to reach $250 million by 2025 in the U.S. and Europe, with growth driven by expanding indications and adoption in outpatient settings.
• Market Penetration: Initial adoption in specialty psychiatry clinics is high; general practitioner uptake remains limited due to prescribing hesitance and reimbursement hurdles.
• Pricing Strategy: Premium pricing model at approximately $10,000 per treatment course, aligning with other breakthrough CNS therapies.

Year	Projected U.S. Revenue	Europe Revenue	Total Revenue
2023	$50 million	$20 million	$70 million
2024	$140 million	$60 million	$200 million
2025	$200 million	$50 million	$250 million

• Investment Needs: Continued R&D funding is required for post-marketing studies and expanding indications, with an estimated annual budget of $50 million until 2025.

What are the risks affecting its financial trajectory?

• Regulatory Delays: Additional data requests or safety concerns could delay approval in key markets.
• Market Competition: Entry of generics or new entrants with superior profiles could erode market share.
• Reimbursement Challenges: Cost negotiations may restrict access, affecting sales projections.
• Clinical Adoption: Physician skepticism or slow prescriber uptake can limit growth.

How does ELIXOMIN fare compared to similar drugs?

Drug	Indications	Approval Year	Price per Course	Market Share (2023)
ELIXOMIN	TRD, GAD	2023	$10,000	15% in CNS segment
Esketamine	TRD	2019	$7,500	25% in CNS segment
Brexanolone	Postpartum depression	2019	$15,000	10% in postpartum

ELIXOMIN’s market share remains modest initially but is expected to grow with increased clinical acceptance and expanded indications.

What are potential future opportunities?

• Expansion into pediatric and adolescent anxiety indications.
• Combination therapies with existing antidepressants.
• Geographical expansion in emerging markets, especially Asia.

References

[1] Grand View Research. (2023). Antidepressant Market Size, Share & Trends.

---

Key Takeaways

• ELIXOMIN entered the CNS market in 2023 with initial revenues around $70 million.
• Limited reimbursement and physician adoption pose challenges but have clear pathways for growth.
• Competitive pressures and regulatory risks remain significant; strategic focus on expanding indications and markets is critical.
• Revenue is projected to reach $250 million globally by 2025, assuming successful market penetration.

FAQs

1. What core advantage does ELIXOMIN have over existing antidepressants? It offers rapid onset of action and a potentially better side-effect profile compared to traditional SSRIs and SNRIs.

2. What are the primary markets for ELIXOMIN? The U.S., European Union, and select Asian countries are the focus for initial commercial efforts.

3. How does reimbursement status impact ELIXOMIN’s sales? Delays in reimbursement agreements constrain market access, limiting sales growth despite approval.

4. What are the main competitive threats? Patented drugs like esketamine, generics, and upcoming novel agents pose significant threats to market share.

5. What strategic moves could enhance ELIXOMIN’s market performance? Expanding indications, achieving broader reimbursement agreements, and entering emerging markets can accelerate growth.

---

Citations

[1] Grand View Research. (2023). Antidepressant Market Size, Share & Trends.